Advanced Biomed Inc. Common Stock cash flow to debt ratio of -14.35% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Advanced Biomed Inc. Common Stock's free cash flow has increased -91.71% from $-2.20M last year to $-182.45K, signaling increasing performance

Advanced Biomed Inc. Common Stock's debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability.

Advanced Biomed Inc. Common Stock's debt has increased relative to shareholder equity from 0.08 last year to 0.08 today, signaling weakened financials

Advanced Biomed Inc. Common Stock has a net cash position, so leverage is healthy.

Advanced Biomed Inc. Common Stock earns at least as much interest as it pays. Interest obligations are fully covered.

Advanced Biomed Inc. Common Stock has insufficient data to evaluate this check.

Advanced Biomed Inc. Common Stock's short-term assets of $6.03M exceed its short-term liabilities of $2.89M

Advanced Biomed Inc. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Advanced Biomed Inc. Common Stock's return on equity of -20.71%, is lower than 15.00%, indicating bad performance

Advanced Biomed Inc. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Advanced Biomed Inc. Common Stock has insufficient public price history to evaluate earnings stability.

Advanced Biomed Inc. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it

Advanced Biomed Inc. Common Stock has negative free cash flow, indicating cash burn

Advanced Biomed Inc. Common Stock's yearly earnings has increased -96.35% since last year from $-2.78M to $-101.52K, signaling increasing performance

Advanced Biomed Inc. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -11.04% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Advanced Biomed Inc. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.

Advanced Biomed Inc. Common Stock has insufficient public price history to evaluate revenue consistency.

Advanced Biomed Inc. Common Stock has insufficient public price history to evaluate ROE consistency.

Advanced Biomed Inc. Common Stock has insufficient data to evaluate this check.

Advanced Biomed Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Advanced Biomed Inc. Common Stock is undervalued relative to its fair value price of 2.68K based on EBITDA multiple model

Advanced Biomed Inc. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Advanced Biomed Inc. Common Stock has insufficient data to evaluate this check.

Advanced Biomed Inc. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Advanced Biomed Inc. Common Stock has a price-to-book ratio of 1.10x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Advanced Biomed Inc. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue